ADENOSINE AXIS – ETRUMADENANT

When A2a and A2b receptors are activated by adenosine, they protect tumor cells from T cells and promote tumor cell proliferation, angiogenesis, and metastasis.

Etrumadenant (etruma) is an investigational small molecule dual antagonist of A2a and A2b receptors, one or both of which is found on T, NK, and myeloid cells. Etrumadenant was designed to block both A2a and A2b receptors to ensure that adenosine signaling would be disrupted on all the immune cells that harbor one or both of the receptors. By blocking both A2a and A2b receptors, etrumadenant is designed to free immune cells from adenosine suppression, unleashing their full strength to fight cancer cells.